title: Role of raltegravir in the management of HIV-1 infection.
abstract: The development of multiple agents with potent antiretroviral activity against HIV has ushered in a new age of optimism in the management of patients infected with the virus. However, the viruses' dynamic ability to develop resistance against these agents necessitates the investigation of novel targets for viral suppression. Raltegravir represents a first-in-class agent targeting the HIV integrase enzyme, which is responsible for integration of virally encoded DNA into the host genome. Over the last 5 years, clinical trials data has demonstrated an increasing role for raltegravir in the management of both treatment-experienced and treatment-naïve HIV-1-infected patients. This review focuses on the evidence supporting raltegravir's efficacy in an array of clinical settings. Other HIV-1 integrase inhibitors in development are also briefly discussed.
authors.affiliation: Duke University Medical Center, Department of Hospital Medicine, Durham Regional Hospital, Durham, North Carolina, USA.
authors.forename: N Lance
authors.initials: NL
authors.lastname: Okeke
authors.forename: Charles
authors.initials: C
authors.lastname: Hicks
references.citation: J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48
references.pmid: 20404738
references.citation: J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6
references.pmid: 19648823
references.citation: AIDS. 2004 Oct 21;18(15):2019-28
references.pmid: 15577623
references.citation: N Engl J Med. 2008 Jul 24;359(4):339-54
references.pmid: 18650512
references.citation: J Antimicrob Chemother. 2010 Feb;65(2):320-6
references.pmid: 20007331
references.citation: AIDS. 2010 Jul 17;24(11):1697-707
references.pmid: 20467288
references.citation: J Infect Dis. 2010 Mar 15;201(6):814-22
references.pmid: 20146631
references.citation: J Infect Chemother. 2011 Feb;17(1):105-10
references.pmid: 20585968
references.citation: Lancet. 2010 Jan 30;375(9712):396-407
references.pmid: 20074791
references.citation: PLoS One. 2010 Apr 01;5(4):e9948
references.pmid: 20376347
references.citation: J Antimicrob Chemother. 2009 Apr;63(4):795-804
references.pmid: 19221102
references.citation: N Engl J Med. 2008 Jul 24;359(4):355-65
references.pmid: 18650513
references.citation: Braz J Infect Dis. 2010 Sep-Oct;14(5):513-8
references.pmid: 21221483
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4
references.pmid: 19667293
references.citation: Clin Infect Dis. 2010 Feb 15;50(4):605-12
references.pmid: 20085491
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8
references.pmid: 18625763
references.citation: J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93
references.pmid: 20300008
references.citation: Clin Drug Investig. 2011;31(5):345-9
references.pmid: 21344955
references.citation: J Antimicrob Chemother. 2010 Nov;65(11):2305-18
references.pmid: 20817922
references.citation: J Virol. 2009 Oct;83(19):10245-9
references.pmid: 19605484
references.citation: J Acquir Immune Defic Syndr. 2010 Oct;55(2):148-55
references.pmid: 20634701
references.citation: J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15
references.pmid: 17133211
references.citation: J Antimicrob Chemother. 2010 Dec;65(12):2485-8
references.pmid: 20852268
references.citation: AIDS. 2008 Jul 11;22(11):1382-4
references.pmid: 18580624
references.citation: Science. 2000 Jan 28;287(5453):646-50
references.pmid: 10649997
references.citation: Int J STD AIDS. 2010 Nov;21(11):783-5
references.pmid: 21187364
references.citation: J Virol. 1998 Jun;72(6):5046-55
references.pmid: 9573274
references.citation: Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2399-403
references.pmid: 8460151
references.citation: J Virol. 2000 Dec;74(23):11191-200
references.pmid: 11070016
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32
references.pmid: 18838586
references.citation: J Virol. 2008 Nov;82(21):10366-74
references.pmid: 18715920
references.citation: PLoS One. 2010 Dec 21;5(12):e15257
references.pmid: 21203568
references.citation: J Virol. 2009 Nov;83(22):11440-6
references.pmid: 19759152
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11233-8
references.pmid: 15277684
references.citation: Clin Infect Dis. 2008 Jul 1;47(1):137-40
references.pmid: 18513146
references.citation: Lancet. 2009 Sep 5;374(9692):796-806
references.pmid: 19647866
references.citation: J Med Chem. 2008 Sep 25;51(18):5843-55
references.pmid: 18763751
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2752-5
references.pmid: 19398643
references.citation: Pharmacol Res. 2011 Mar;63(3):249-53
references.pmid: 21130167
references.citation: Proc Natl Acad Sci U S A. 2002 May 14;99(10):6661-6
references.pmid: 11997448
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4275-82
references.pmid: 19651917
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6
references.pmid: 19433563
references.citation: Nat Rev Drug Discov. 2005 Mar;4(3):236-48
references.pmid: 15729361
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):367-73
references.pmid: 19487951
references.citation: J Infect. 2010 Jul;61(2):189-90
references.pmid: 20447415
references.citation: Lancet. 2007 Apr 14;369(9569):1261-1269
references.pmid: 17434401
references.citation: J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33
references.pmid: 17721395
references.citation: Antiviral Res. 2010 Jan;85(1):101-18
references.pmid: 19925830
references.citation: Antimicrob Agents Chemother. 2009 May;53(5):1747-52
references.pmid: 19223645
references.citation: HIV Clin Trials. 2010 Jul-Aug;11(4):197-204
references.pmid: 20974575
references.citation: PLoS One. 2010 Apr 26;5(4):e10311
references.pmid: 20436677
references.citation: J Virol. 2003 Nov;77(21):11459-70
references.pmid: 14557631
references.citation: Retrovirology (Auckl). 2008 Nov 5;2:11-16
references.pmid: 19915684
references.citation: Antimicrob Agents Chemother. 2010 Jul;54(7):3047-8
references.pmid: 20439608
references.citation: Antimicrob Agents Chemother. 2010 Jan;54(1):491-501
references.pmid: 19901095
references.citation: PLoS Med. 2010 Aug 10;7(8):
references.pmid: 20711481
references.citation: Nat Med. 2010 Apr;16(4):460-5
references.pmid: 20228817
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4338-43
references.pmid: 18838589
references.citation: J Virol. 2004 May;78(10):5045-55
references.pmid: 15113886
references.citation: AIDS. 2010 Jan 28;24(3):473-5
references.pmid: 20087078
references.citation: J Clin Pharmacol. 2011 Oct;51(10):1376-402
references.pmid: 21209233
references.citation: Antimicrob Agents Chemother. 2011 Feb;55(2):813-21
references.pmid: 21115794
references.citation: J Virol. 1997 Sep;71(9):7005-11
references.pmid: 9261430
references.citation: PLoS One. 2009 Sep 01;4(9):e6877
references.pmid: 19721718
references.citation: Antiviral Res. 2010 Dec;88(3):281-6
references.pmid: 20883724
references.citation: J Clin Pharmacol. 2008 Feb;48(2):209-14
references.pmid: 18077730
references.citation: J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):456-63
references.pmid: 20306554
references.citation: Clin Infect Dis. 2010 Mar 15;50(6):912-9
references.pmid: 20156060
references.citation: AIDS. 2010 Oct 23;24(16):2581-3
references.pmid: 20960678